
    Original Text: Patients should be considered platinum-refractory (progression while on a prior platinum chemotherapy) or resistant (persistence or recurrence within 6 months after a prior platinum chemotherapy) and be deemed unlikely to have significant benefit from any standard therapies by the treating investigator
    Disease/Condition: none
    Procedure: none
    Drug: none
    Biomarker: none
    Computable Rule: "Platinum Refractory OR Resistant AND Unlikely To Benefit" is True

Criterion:
    Patients with histologically confirmed advanced non-small cell lung cancer (NSCLC), adenocarcinoma, squamous cell carcinoma, large cell carcinoma, or other NSCLC subtypes, who have progressed following treatment with at least one platinum-based regimen and at least one taxane-containing regimen

Output:
    Original Text: Patients with histologically confirmed advanced non-small cell lung cancer (NSCLC), adenocarcinoma, squamous cell carcinoma, large cell car